Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes.(Recently Published Abstracts)(Author abstract) From: Alternative Medicine Review | Date: September 1, 2006| Author: | COPYRIGHT 2006 Thorne Research Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

Hedman M. Ludvigsson ,J. Faresjo M K. J Interferon Cytokine Res 2006:26:207-213.

Type 1 diabetes (T1D) is an autoimmune disease suggested to be of a T helper (Th)l-like origin. This study aimed to investigate the Thl-like and Th2-like profile in high-risk individuals during the prediabetic phase and the immunologic effect of treatment with nicotinamide. Highrisk first-degree relatives of T1D patients participating in the European Nicotinamide Diabetes Intervention Trial (ENDIT) were treated with either nicotinamide or placebo. Peripheral blood mononuclear cells (PBMC) were ...